SE0401031D0 - A new glucocorticoid replacement therapy - Google Patents

A new glucocorticoid replacement therapy

Info

Publication number
SE0401031D0
SE0401031D0 SE0401031A SE0401031A SE0401031D0 SE 0401031 D0 SE0401031 D0 SE 0401031D0 SE 0401031 A SE0401031 A SE 0401031A SE 0401031 A SE0401031 A SE 0401031A SE 0401031 D0 SE0401031 D0 SE 0401031D0
Authority
SE
Sweden
Prior art keywords
glucocorticoid
glucocorticoids
relates
replacement therapy
treatment
Prior art date
Application number
SE0401031A
Other languages
English (en)
Swedish (sv)
Inventor
Stanko Skrtic
Joergen Johnsson
Hans Lennernaes
Thomas Hedner
Gudmundur Johannsson
Original Assignee
Duocort Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duocort Ab filed Critical Duocort Ab
Priority to SE0401031A priority Critical patent/SE0401031D0/xx
Publication of SE0401031D0 publication Critical patent/SE0401031D0/xx
Priority to PL05735076T priority patent/PL1744730T3/pl
Priority to ES05735076.1T priority patent/ES2600556T3/es
Priority to RS20160749A priority patent/RS55198B1/sr
Priority to AU2005235370A priority patent/AU2005235370B2/en
Priority to BRPI0510044A priority patent/BRPI0510044B8/pt
Priority to MXPA06012011A priority patent/MXPA06012011A/es
Priority to DK05735076.1T priority patent/DK1744730T3/en
Priority to HRP20161380TT priority patent/HRP20161380T1/hr
Priority to ES16169413T priority patent/ES2857600T3/es
Priority to MEP-2016-250A priority patent/ME02584B/me
Priority to EP05735076.1A priority patent/EP1744730B1/en
Priority to RS20210233A priority patent/RS61501B1/sr
Priority to PT161694138T priority patent/PT3072507T/pt
Priority to PT57350761T priority patent/PT1744730T/pt
Priority to US11/587,514 priority patent/US8425937B2/en
Priority to NZ585340A priority patent/NZ585340A/en
Priority to HUE05735076A priority patent/HUE030546T2/en
Priority to JP2007508863A priority patent/JP5149618B2/ja
Priority to MX2013004889A priority patent/MX344197B/es
Priority to HUE16169413A priority patent/HUE053248T2/hu
Priority to CA2564000A priority patent/CA2564000C/en
Priority to DK16169413.8T priority patent/DK3072507T3/da
Priority to PCT/EP2005/004400 priority patent/WO2005102271A2/en
Priority to CN201210499801.8A priority patent/CN103006592B/zh
Priority to LTEP16169413.8T priority patent/LT3072507T/lt
Priority to SI200532291T priority patent/SI3072507T1/sl
Priority to CN2005800118623A priority patent/CN1942176B/zh
Priority to LTEP05735076.1T priority patent/LT1744730T/lt
Priority to EP16169413.8A priority patent/EP3072507B1/en
Priority to SG2013005244A priority patent/SG188081A1/en
Priority to PL16169413T priority patent/PL3072507T3/pl
Priority to IL178776A priority patent/IL178776A/en
Priority to ZA200609680A priority patent/ZA200609680B/xx
Priority to JP2012173158A priority patent/JP5681679B2/ja
Priority to US13/722,013 priority patent/US20130129823A1/en
Priority to HK13106780.6A priority patent/HK1179525B/xx
Priority to IL227375A priority patent/IL227375A/en
Priority to US14/255,332 priority patent/US10583146B2/en
Priority to CY20161101091T priority patent/CY1118275T1/el
Priority to HRP20210348TT priority patent/HRP20210348T1/hr
Priority to CY20211100191T priority patent/CY1124074T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
SE0401031A 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy SE0401031D0 (sv)

Priority Applications (42)

Application Number Priority Date Filing Date Title
SE0401031A SE0401031D0 (sv) 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy
PL16169413T PL3072507T3 (pl) 2004-04-22 2005-04-21 Kompozycje farmaceutyczne do glikokortykoidowej terapii zastępczej
HUE16169413A HUE053248T2 (hu) 2004-04-22 2005-04-21 Gyógyszerészeti készítmények glükokortikoid helyettesítõ terápiára
CA2564000A CA2564000C (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
RS20160749A RS55198B1 (sr) 2004-04-22 2005-04-21 Farmaceutske kompozicije za terapiju zamene glukokortikoida
AU2005235370A AU2005235370B2 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
BRPI0510044A BRPI0510044B8 (pt) 2004-04-22 2005-04-21 composição farmacêutica, e, uso de uma composição farmacêutica
MXPA06012011A MXPA06012011A (es) 2004-04-22 2005-04-21 Composiciones farmaceuticas para la terapia de reemplazo de glucocorticoides.
DK05735076.1T DK1744730T3 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
HRP20161380TT HRP20161380T1 (hr) 2004-04-22 2005-04-21 Farmaceutski sastavi za zamjensku terapiju glukokortikoidima
ES16169413T ES2857600T3 (es) 2004-04-22 2005-04-21 Composiciones farmacéuticas para terapia de reemplazo con glucocorticoides
MEP-2016-250A ME02584B (me) 2004-04-22 2005-04-21 Farmaceutske kompozicije za terapiju zamene glukokortikoida
EP05735076.1A EP1744730B1 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
RS20210233A RS61501B1 (sr) 2004-04-22 2005-04-21 Farmaceutske kompozicije za terapiju zamene glukokortikoida
PT161694138T PT3072507T (pt) 2004-04-22 2005-04-21 Composições farmacêuticas para terapia de substituição de glucocorticóide
PT57350761T PT1744730T (pt) 2004-04-22 2005-04-21 Composições farmacêuticas para terapia de substituição de glucocorticoide
US11/587,514 US8425937B2 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
NZ585340A NZ585340A (en) 2004-04-22 2005-04-21 Coated tablet composition comprising a coat for immediate release glucocorticoid and a core for extended release glucocorticoid for glucocorticoid replacement therapy
HUE05735076A HUE030546T2 (en) 2004-04-22 2005-04-21 A pharmaceutical composition for glucocorticoid replacement therapy
JP2007508863A JP5149618B2 (ja) 2004-04-22 2005-04-21 グルココルチコイド代償療法用の医薬組成物
MX2013004889A MX344197B (es) 2004-04-22 2005-04-21 Composiciones farmaceuticas para la terapia de reemplazo de glucocorticoides.
PL05735076T PL1744730T3 (pl) 2004-04-22 2005-04-21 Kompozycje farmaceutyczne do glikokortykoidowej terapii zastępczej
PCT/EP2005/004400 WO2005102271A2 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
ES05735076.1T ES2600556T3 (es) 2004-04-22 2005-04-21 Sustitución de las composiciones farmacéuticas para la terapia con glucocorticoides
DK16169413.8T DK3072507T3 (da) 2004-04-22 2005-04-21 Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
CN201210499801.8A CN103006592B (zh) 2004-04-22 2005-04-21 用于糖皮质激素替代疗法的药物组合物
LTEP16169413.8T LT3072507T (lt) 2004-04-22 2005-04-21 Farmacinės kompozicijos, skirtos pakaitinei gliukokortikoidų terapijai
SI200532291T SI3072507T1 (sl) 2004-04-22 2005-04-21 Farmacevtski sestavek za nadomestno zdravljenje z glukokortikoidi
CN2005800118623A CN1942176B (zh) 2004-04-22 2005-04-21 用于糖皮质激素替代疗法的药物组合物
LTEP05735076.1T LT1744730T (lt) 2004-04-22 2005-04-21 Farmacinės kompozicijos, skirtos pakaitinei gliukokortikoidų terapijai
EP16169413.8A EP3072507B1 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
SG2013005244A SG188081A1 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
IL178776A IL178776A (en) 2004-04-22 2006-10-19 Dosage form of tablet coated with glucocorticoid replacement therapy
ZA200609680A ZA200609680B (en) 2004-04-22 2006-11-21 Pharmaceutical compositions for glucocorticoid replacement therapy
JP2012173158A JP5681679B2 (ja) 2004-04-22 2012-08-03 グルココルチコイド代償療法用の医薬組成物
US13/722,013 US20130129823A1 (en) 2004-04-22 2012-12-20 Pharmaceutical compositions for glucocorticoid replacement therapy
HK13106780.6A HK1179525B (en) 2004-04-22 2013-06-07 Pharmaceutical compositions for glucocorticoid replacement therapy
IL227375A IL227375A (en) 2004-04-22 2013-07-08 Dosage form of tablet coated with glucocorticoid replacement therapy
US14/255,332 US10583146B2 (en) 2004-04-22 2014-04-17 Pharmaceutical compositions for glucocorticoid replacement therapy
CY20161101091T CY1118275T1 (el) 2004-04-22 2016-10-26 Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων
HRP20210348TT HRP20210348T1 (hr) 2004-04-22 2021-03-01 Farmaceutski sastavi za terapiju zamjene glukokortikoida
CY20211100191T CY1124074T1 (el) 2004-04-22 2021-03-05 Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56420504P 2004-04-22 2004-04-22
SE0401031A SE0401031D0 (sv) 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy

Publications (1)

Publication Number Publication Date
SE0401031D0 true SE0401031D0 (sv) 2004-04-22

Family

ID=35197481

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401031A SE0401031D0 (sv) 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy

Country Status (25)

Country Link
US (3) US8425937B2 (cg-RX-API-DMAC7.html)
EP (2) EP3072507B1 (cg-RX-API-DMAC7.html)
JP (2) JP5149618B2 (cg-RX-API-DMAC7.html)
CN (2) CN1942176B (cg-RX-API-DMAC7.html)
AU (1) AU2005235370B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510044B8 (cg-RX-API-DMAC7.html)
CA (1) CA2564000C (cg-RX-API-DMAC7.html)
CY (2) CY1118275T1 (cg-RX-API-DMAC7.html)
DK (2) DK1744730T3 (cg-RX-API-DMAC7.html)
ES (2) ES2857600T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20161380T1 (cg-RX-API-DMAC7.html)
HU (2) HUE030546T2 (cg-RX-API-DMAC7.html)
IL (2) IL178776A (cg-RX-API-DMAC7.html)
LT (2) LT3072507T (cg-RX-API-DMAC7.html)
ME (1) ME02584B (cg-RX-API-DMAC7.html)
MX (2) MXPA06012011A (cg-RX-API-DMAC7.html)
NZ (1) NZ585340A (cg-RX-API-DMAC7.html)
PL (2) PL3072507T3 (cg-RX-API-DMAC7.html)
PT (2) PT3072507T (cg-RX-API-DMAC7.html)
RS (2) RS61501B1 (cg-RX-API-DMAC7.html)
SE (1) SE0401031D0 (cg-RX-API-DMAC7.html)
SG (1) SG188081A1 (cg-RX-API-DMAC7.html)
SI (1) SI3072507T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005102271A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200609680B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925139B2 (en) 2004-04-22 2018-03-27 Acucort Ab Pharmaceutical compositions for acute glucocorticoid therapy
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
WO2007067494A1 (en) * 2005-12-06 2007-06-14 Monosol Rx, Llc Topical film compositions for delivery of actives
FR2926722B1 (fr) * 2008-01-25 2010-09-03 Substipharm Dev Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone
DK2151235T3 (da) * 2008-07-21 2011-04-11 Falk Pharma Gmbh Farmaceutisk formulering til behandling af den øvre fordøjelseskanal
SG174583A1 (en) 2009-04-07 2011-10-28 Duocort Pharma Ab Improved glucocorticoid therapy
BR112012029466A2 (pt) * 2010-05-20 2017-03-01 Duocort Phama Ab "composição de glicocorticoide, método melhorado para tratar a deficiência de glicocorticoide, e, método para dar origem a uma dosagem individualizada de glicocorticoides"
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201202433D0 (en) * 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
JP2014086673A (ja) 2012-10-26 2014-05-12 Mitsubishi Electric Corp モノリシック集積回路
EP2914255B1 (en) 2012-11-02 2021-07-21 Murray & Poole Enterprises, Ltd. Treatment or prevention of cardiovascular events via the administration of colchicine
CA2909370A1 (en) 2013-04-16 2014-10-23 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
ES2870718T3 (es) * 2013-04-16 2021-10-27 Murray & Poole Entpr Ltd Formulación de liberación mantenida de la colchicina y métodos para establecer los mismos
GB201308933D0 (en) * 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
MX348595B (es) * 2013-08-02 2017-06-21 Laboratorio Raam De Sahuayo S A De C V Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
RS58543B2 (sr) 2013-12-23 2023-02-28 Dr Falk Pharma Gmbh Optimizovana farmaceutska formulacija za lečenje zapaljenskih promena ezofagusa
EP3277281B1 (en) * 2015-03-30 2022-01-05 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
CN107115308B (zh) * 2016-02-23 2021-02-23 天津金耀集团有限公司 一种氢化可的松双相缓释片剂组合物
RU2748437C2 (ru) * 2019-10-28 2021-05-25 Федеральное государственное бюджетное учреждение науки Институт цитологии Российской академии наук (ИНЦ РАН) Производное гидрокортизона в качестве средства для лечения болезни Альцгеймера
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260384C3 (de) * 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
PT745382E (pt) * 1994-01-31 2004-04-30 Yamanouchi Pharma Co Ltd Forma moldada por compressao com solubilidade intra-oral e processo para a sua producao
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6156743A (en) 1999-10-18 2000-12-05 Whitcomb; John E. Method of decreasing fatigue
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
US20030190360A1 (en) * 2001-03-13 2003-10-09 Baichwal Anand R. Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment
CA2441007C (en) * 2001-03-15 2009-06-09 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003215110B2 (en) 2002-02-07 2007-11-29 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US9925139B2 (en) 2004-04-22 2018-03-27 Acucort Ab Pharmaceutical compositions for acute glucocorticoid therapy
GB0623740D0 (en) 2006-11-28 2007-01-10 Diurnal Ltd Treatment of disease
SG174583A1 (en) 2009-04-07 2011-10-28 Duocort Pharma Ab Improved glucocorticoid therapy
BR112012029466A2 (pt) 2010-05-20 2017-03-01 Duocort Phama Ab "composição de glicocorticoide, método melhorado para tratar a deficiência de glicocorticoide, e, método para dar origem a uma dosagem individualizada de glicocorticoides"

Also Published As

Publication number Publication date
PL3072507T3 (pl) 2021-07-19
RS61501B1 (sr) 2021-03-31
EP3072507A1 (en) 2016-09-28
HRP20161380T1 (hr) 2016-12-02
BRPI0510044B1 (pt) 2019-01-29
PT1744730T (pt) 2016-10-07
HUE030546T2 (en) 2017-05-29
JP5149618B2 (ja) 2013-02-20
JP2012236846A (ja) 2012-12-06
CN1942176B (zh) 2013-09-18
EP1744730B1 (en) 2016-08-03
US20140242167A1 (en) 2014-08-28
LT3072507T (lt) 2021-02-25
CA2564000A1 (en) 2005-11-03
ES2857600T3 (es) 2021-09-29
US20130129823A1 (en) 2013-05-23
SI3072507T1 (sl) 2021-04-30
HUE053248T2 (hu) 2021-06-28
CN103006592A (zh) 2013-04-03
US20080187586A1 (en) 2008-08-07
HRP20210348T1 (hr) 2021-04-16
CA2564000C (en) 2013-07-02
CN1942176A (zh) 2007-04-04
PT3072507T (pt) 2021-02-23
WO2005102271A3 (en) 2006-08-03
BRPI0510044B8 (pt) 2021-05-25
DK1744730T3 (en) 2016-08-29
ES2600556T3 (es) 2017-02-09
CY1124074T1 (el) 2022-03-24
US10583146B2 (en) 2020-03-10
JP5681679B2 (ja) 2015-03-11
EP3072507B1 (en) 2020-12-23
HK1179525A1 (zh) 2013-10-04
IL178776A (en) 2013-10-31
LT1744730T (lt) 2016-10-25
PL1744730T3 (pl) 2017-01-31
CN103006592B (zh) 2016-03-02
EP1744730A2 (en) 2007-01-24
ZA200609680B (en) 2008-08-27
DK3072507T3 (da) 2021-02-08
WO2005102271A2 (en) 2005-11-03
JP2007533698A (ja) 2007-11-22
MX344197B (es) 2016-12-08
AU2005235370A1 (en) 2005-11-03
AU2005235370B2 (en) 2011-06-09
IL178776A0 (en) 2007-02-11
CY1118275T1 (el) 2017-06-28
RS55198B1 (sr) 2017-01-31
NZ585340A (en) 2012-04-27
ME02584B (me) 2017-06-20
US8425937B2 (en) 2013-04-23
SG188081A1 (en) 2013-03-28
MXPA06012011A (es) 2007-04-16
BRPI0510044A (pt) 2007-10-16
IL227375A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
CY1124074T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων
ATE450251T1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
ATE529125T1 (de) Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
ATE544460T1 (de) Zusammensetzungen und verfahren für eine gesunde schwangerschaft
EA200600254A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
MX340538B (es) Compuestos amido y sus usos como farmaceuticos.
NO20072322L (no) Laktamforbindelser og anvendelse derav som farmasoytiske midler
SG163518A1 (en) Amido compounds and their use as pharmaceuticals
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
Becker et al. Quality of life in oral cancer patients–effects of mandible resection and socio-cultural aspects
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
Rodrigues et al. Long-term dose-and time-dependent effects of endodontic sealers in human in vitro osteoclastogenesis
SG160425A1 (en) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
EP1885371A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão
DE602006009786D1 (de) Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
WO2006102979A3 (de) Entzündungsmarker und kombinationen davon als biochemische marker bei kardiovaskulären erkrankungen
BRPI0419229A (pt) derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica
MY151438A (en) Compositions and method for treatment of tumors